参考文献
(在框内滑动手指即可浏览)
[1] 中华医学会外科学分会胃肠外科学组, 中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会, 中国临床肿瘤学会胃肠间质瘤专家委员会, 等. 胃肠间质瘤全程化管理中国专家共识(2020版)[J]. 中国实用外科杂志, 2020,40(10):1109-1119.
[2] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃肠间质瘤诊疗指南2020[M]. 北京:人民卫生出版社, 2020.
[3] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology:Gastrointestinal Stromal Tumors (GISTs), Version 1.2021[S/OL].(2020-10-30)[2021-01-23].https://www.nccn.org/professionals/physician_gls/default.aspx#gist
[4] 中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版) [J]. 肿瘤综合治疗电子杂志,2018,4(1):31-43.
[5] 中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会, 中华医学会外科学分会胃肠外科学组. 胃肠间质瘤规范化外科治疗中国专家共识(2018 版)[J]. 中国实用外科杂志, 2018,38(9):965-973.
[6] Boikos SA, Pappo AS, Killian JK, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: A report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic[J]. JAMA Oncol, 2016, 2(7):922-928.
[7] Hou YY, Lu SH, Zhou Y, et al. Predictive values of clinical and pathological parameters for malignancy of gastrointestinal stromal tumors[J]. Histol Histopathol, 2009, 24(6):737-747.
[8] 曹晖, 汪明. 胃肠间质瘤综合诊治中若干焦点问题思考 [J]. 中国实用外科杂志, 2018, 38(5):485-493.
[9] 徐皓, 马利林, 徐为, 等. 胃肠间质瘤患者服药前后检测伊马替尼血浆浓度意义的中国多中心研究[J]. 中华胃肠外科杂志, 2016, 19(11):1271-1276.
[10] Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial[J]. JAMA, 2012, 307(12): 1265-1272.
[11] Raut CP, Espat J, Maki RG, et al. Extended treatment with adjuvant imatinib for patients with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study[J]. JAMA Oncol, 2018, 4(12):e184060.
[12] Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial[J]. Lancet Oncol, 2020, 21(7):935-946.
[13] Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(7):923-934.